Susan M Wrubel, PA-C
Physician Assistant · Mountain View
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Susan M Wrubel’s office at (650) 988-7488 to ask if they take your plan before you enroll.
Drugs they prescribed that Part D paid
$9,041
Pharmacies billed $9,041 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 221) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
207 generic and fewer than 11 brand-name prescriptions · $9,041 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Duloxetine | 11 | $229 | $21 |
| Sertraline | 16 | $185 | $12 |
| Trazodone | 19 | $44 | $2 |
| Lorazepam | 16 | $42 | $3 |
Year by year
| 2024 | 221 | 30 | 0% (0) | None | $9,041 |
| 2023 | 338 | 53 | None | None | $18,878 |
| 2022 | 305 | 88 | 4% (13) | None | $27,810 |
| 2021 | 221 | 64 | None | 15% | $13,412 |
| 2020 | 210 | 57 | None | 17% | $11,159 |
| 2019 | 174 | 51 | None | 9% | $10,253 |
| 2018 | 101 | 60 | None | None | $11,070 |
| 2017 | 31 | 16 | None | None | $1,520 |
| 2016 | 47 | 25 | None | None | $97,913 |
| 2015 | 42 | 21 | None | 26% | $2,230 |
| 2014 | 60 | 24 | None | 33% | $6,819 |
| 2013 | 86 | 34 | 0% (0) | 27% | $25,568 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Synthroid | 11 | $1,286 | $117 |
| Pregabalin | 11 | $602 | $55 |
| Duloxetine | 11 | $300 | $27 |
| Valsartan | 12 | $164 | $14 |
| Sertraline | 17 | $156 | $9 |
| Escitalopram | 13 | $76 | $6 |
| Trazodone | 16 | $72 | $4 |
| Metformin | 12 | $21 | $2 |
2022: 4 drugs
| Celecoxib | 15 | $1,102 | $73 |
| Indapamide | 12 | $471 | $39 |
| Trazodone | 17 | $314 | $18 |
| Zolpidem | 12 | $107 | $9 |
2021: 1 drug
| Risperidone | 16 | $343 | $21 |
2020: 2 drugs
| Valsartan | 11 | $685 | $62 |
| Synthroid | 11 | $622 | $57 |
2018: 1 drug
| Pantoprazole | 12 | $208 | $17 |
Money from drug and device companies
$176 in 2025
| 2025 | 4 | 4 | None | $176 |
| 2024 | 9 | 10 | None | $818 |
| 2023 | 12 | 25 | None | $1,234 |
| 2022 | 17 | 90 | None | $2,135 |
| 2021 | 16 | 64 | None | $1,670 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Epclusa | $106 | 1 payment
|
| Lundbeck | Rexulti | $30 | 1 payment
|
| Abbvie | Vraylar | $26 | 1 payment
|
| Astellas Pharma US | Veozah | $14 | 1 payment
|
See all 4 published payments
| Astellas Pharma US | Meals · 2025-04-29 | Veozah | $14 |
| Abbvie | Meals · 2025-02-19 | Vraylar | $26 |
| Gilead Sciences | Meals · 2025-02-19 | Epclusa | $106 |
| Lundbeck | Meals · 2025-01-16 | Rexulti | $30 |
See earlier years (2024, 2023, 2022, 2021)
2024: $818
| Abbvie | Vraylar | $133 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $122 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | None | $122 | 1 payment
|
| Gilead Sciences | Epclusa | $122 | 1 payment
|
| Sage Therapeutics | None | $96 | 1 payment
|
| Biogen | Spinraza | $93 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $87 | 1 payment
|
| Axsome Therapeutics | Auvelity | $28 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $15 | 1 payment
|
2023: $1,234
| Abbvie | Vraylar | $539 | 13 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $231 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $106 | 1 payment
|
| Amgen | Amjevita | $105 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $99 | 1 payment
|
| Vanda Pharmaceuticals | Hetlioz | $30 | 1 payment
|
| Axsome Therapeutics | Auvelity | $29 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $20 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $20 | 1 payment
|
| Iti | Caplyta | $19 | 1 payment
|
| Alkermes | Aristada | $15 | 1 payment
|
2022: $2,135
| Abbvie | Vraylar | $367 | 20 payments
|
| Amgen | Evenity | $308 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $189 | 9 payments
|
| Iti | Caplyta | $149 | 6 payments
|
| Neurocrine Biosciences | Ingrezza | $140 | 6 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $137 | 5 payments
|
| Sunovion Pharmaceuticals | Latuda | $130 | 11 payments
|
| Vanda Pharmaceuticals | Fanapt | $117 | 4 payments
|
| Lundbeck | Rexulti | $109 | 5 payments
|
| Corium | Azstarys | $108 | 5 payments
|
| Alkermes | Aristada | $98 | 4 payments
|
| Bausch Health US | Aplenzin | $93 | 4 payments
|
| Avanir Pharmaceuticals | Nuedexta | $80 | 3 payments
|
| Alfasigma USA | None | $46 | 2 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $25 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $21 | 1 payment
|
| Almatica Pharma | Sertraline Hcl | $18 | 1 payment
|
2021: $1,670
| Janssen Pharmaceuticals | Invega Sustenna | $302 | 11 payments
|
| AbbVie | Vraylar | $241 | 10 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $181 | 8 payments
|
| Iti | Caplyta | $152 | 5 payments
|
| Jazz Pharmaceuticals | Sunosi | $139 | 2 payments
|
| Sunovion Pharmaceuticals | Latuda | $126 | 7 payments
|
| Adlon Therapeutics L.P. | Adhansia Xr | $111 | 5 payments
|
| Neurocrine Biosciences | Ingrezza | $78 | 3 payments
|
| Alfasigma USA | None | $71 | 3 payments
|
| Coloplast | Restorelle | $62 | 1 payment
|
| Vanda Pharmaceuticals | Fanapt | $57 | 2 payments
|
| Alkermes | Lybalvi | $49 | 2 payments
|
| Bausch Health US | Wellbutrin | $37 | 2 payments
|
| Almatica Pharma | Gralise | $25 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $24 | 1 payment
|
| Eisai | Dayvigo | $16 | 1 payment
|
Professional record
- NPI
- 1245466655
- Licence
- CA PA12112
More record details
- Sole proprietor
- Yes
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 2490 Hospital Dr, Ste 211, Mountain View, CA, 94040
- NPI first listed
- 2009-06-01
- NPI last updated
- 2009-06-01
This is when the NPI record was last certified, not a medical board exam.